BioWorld Asia

Sep. 30, 2009

View Archived Issues

Qiagen's $130M Purchase of DxS a 13X Profit for Investors

LONDON - There was a record return for all the investors in companion diagnostics pioneer DxS Ltd., when the company was acquired last week by Qiagen NV for a total of up to $130 million. (BioWorld International) Read More

J&J Buys $444M Stake in Crucell; Focus on Flu Vaccine and mAbs

Read More

Repair Qualities of Macrophages, Hope for Muscle Regeneration

Read More

Rhucin Gains Ground as It Nears EMEA Action in HAE

Read More

NicOx Submits Naproxcinod's NDA; Celebrex in Crosshairs

Read More

Abbott Makes $6.6B Cash Bid for Solvay's Drug Unit

Read More

Marinomed, Bioalvo Collaborate on Drug Discoveries from the Sea

Read More

On the March: Vaccines Make it Big After H1N1 Scare

Read More

2009 Vaccine Deals

Read More

CHMP Gives Unanimous Backing for Yondelis in Ovarian Cancer

Read More

Other News To Note

Read More